AI Cloud is an AI-driven biotechnology company specializing in antibody discovery and therapeutic development for oncology and neurodegenerative diseases. Our platform integrates Deep Mutational Scanning (DMS), high-throughput phenotyping (FACS, live-cell imaging), SPR-based interaction analysis, and NGS with advanced AI models to map genotype–phenotype relationships at scale. This combined experimental–computational approach enables rapid identification and optimization of antibody candidates with improved affinity, specificity, and developability. We aim to accelerate discovery timelines and reduce cost by generating predictive insights earlier in the R&D process. AI Cloud is seeking global partners for antibody discovery collaborations, DMS-based optimization projects, and co-development of therapeutic programs.